Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140813 | 0.78 | TAAR1 (0.55) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL1086542 | 0.77 | TSHR (0.42) | PYCR1KIF11TSHR | |
| SCHEMBL3633317 | 0.77 | MIF (0.53) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL5539099 | 0.77 | TAAR1 (0.48) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL246959 | 0.77 | TAAR1 (0.48) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL3246600 | 0.77 | TAAR1 (0.54) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL3208460 | 0.75 | TAAR1 (0.55) | TAAR1IDO1MAOBMIFALDH1A1 | |
| SCHEMBL23796962 | 0.74 | PYCR1 (0.47) | PYCR1TAAR1IDO1MAOBMIF | |
| SCHEMBL19690421 | 0.74 | PYCR1 (0.59) | PYCR1TAAR1IDO1MAOBALDH1A1 | |
| SCHEMBL28039087 | 0.74 | IDO1 (0.53) | PYCR1TAAR1IDO1MAOBMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626043-B1 | Heterocyclic thioesters | MGI GP INC (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1083873-B1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | MGI GP INC (US) | 2006-08-09 | — | — | EP | claimed |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873697-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738637-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-07-07 | — | — | US | disclosed |
| CN-105461589-A | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI AVENTIS | 2016-04-06 | — | — | CN | disclosed |
| CN-105418450-A | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS | 2016-03-23 | — | — | CN | disclosed |
| US-20100069244-A1 | Pyridine Compounds for Combating Pests | BASF SE (DE) | 2010-03-18 | — | — | US | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | PYCR1 609/4885TAAR1 4275/4885IDO1 371/4885 |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | PYCR1 609/4885TAAR1 4275/4885IDO1 371/4885 |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | PYCR1 609/4885TAAR1 4275/4885IDO1 371/4885 |
| US-20160194315-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | PYCR1 609/4885TAAR1 4275/4885IDO1 371/4885 |
| US-10174026-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | PYCR1 609/4885TAAR1 4275/4885IDO1 371/4885 |
| US-20100069244-A1 | Pyridine Compounds for Combating Pests | CHRM1, PRDX1, CHRM2 | PYCR1 30/4885TAAR1 52/4885IDO1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.